European Pharmaceutical Review

SEPTEMBER 1, 2023

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029.

Marketing 110

Marketing Sales Competition Pharmaceutical 110

European Pharmaceutical Review

AUGUST 21, 2023

Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. GSK Furthermore, biopharma firm GSK reported +4 percent and +11 percent ex COVID sales in the second quarter of 2023. Drugs Verzenio, Jardiance and Taltz led this result.

Biopharma 98

Biopharma Marketing Sales Medicine 98

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Quantified

SEPTEMBER 21, 2023

through 2029. Part of that growth comes from using AI tools for professional work, especially sales. According to Gartner, 75% of B2B sales organizations will augment traditional playbooks with AI by 2025 despite the current low adoption rate. Competitive pressure will drive companies to invest in AI tools for sales.

Sales 52

Sales Prospecting Training Sales tools 52

pharmaphorum

SEPTEMBER 30, 2022

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029.

Marketing 59

Marketing Sales Competition FDA 59

Pharmaceutical Technology

APRIL 24, 2023

While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98 billion in 2029, while Calquence is expected to make $5.31

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

Pharmaceutical Technology

JUNE 13, 2023

According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029.

Patients 52

Patients Sales Competition Safety 52